Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

June 30, 2009

Conditions
Skin DiseasesCarcinoma, Squamous Cell
Interventions
DRUG

cetuximab

Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.

Trial Locations (14)

14000

Hospital of Caen, Caen

28018

Hospital of Chartres, Chartres

35000

Hospital Pontchaillou, Rennes

35042

Eugène Marquis Center, Rennes

51100

Hospital of Reims, Reims

63058

Hospital Hôtel Dieu, Clermont-Ferrand

68000

CHR of Colmar, Colmar

75006

Hospital Tarnier-Cochin, Paris

75010

Hospital Saint Louis, Department of P. Morel, Paris

Hospital Saint-Louis, department of L. Dubertret, Paris

75018

Hospital Bichat, Paris

76000

Hospital Charles Nicolle, Rouen

92110

Beaujon's Hospital, Clichy

94000

Hospital Henri Mondor, Créteil

All Listed Sponsors
collaborator

Hospital of Chartres- France

UNKNOWN

lead

Centre Hospitalier of Chartres

OTHER

NCT00240682 - Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR | Biotech Hunter | Biotech Hunter